New hope for Tough-to-Treat ewing sarcoma: early trial of xaluritamig begins
NCT ID NCT07297979
First seen Jan 04, 2026 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This early-phase trial is testing a drug called xaluritamig in about 50 people with Ewing sarcoma that has returned or not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body and look for any signs that it might be fighting the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
-
Chris OBrien Lifehouse
RECRUITINGCamperdown, New South Wales, 2050, Australia
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Perth Childrens Hospital
RECRUITINGNedlands, Western Australia, 6009, Australia
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, Victoria, 3000, Australia
-
University of California Los Angeles
RECRUITINGLos Angeles, California, 90995-1752, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
xaluritamig (a drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for Ewing sarcoma that has stopped responding to standard therapy.
What could go wrong
This is a very early phase 1 trial with only 50 participants, so it is primarily testing safety and dosing. It may not show strong anti-cancer effects, and side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.